Development of immunotherapeutic strategies for HIV-1

Bibliography

• GOTCH F, HARDY G, IMAMI N: Therapeutic vaccines in HIV-1 infection. Iminuria Rev (1999) 170:173–182.
   PubMed Web of Science ®Google Scholar
• PALELLA FJ, DELANEY KM, MOORMAN etal.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N ErigL J. Med. (1998) 338:853–860.
   Google Scholar
• VITTINGHOFF E, SCHEER S, O'MALLEY E COLFAX G, HOLMBERG SD, BUCHBINDER SP: Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J. Infect. Dis. (1999) 179:717–720.
   PubMed Web of Science ®Google Scholar
• LEDERMAN MM, VALDEZ H. Immune restoration with antiretroviral therapies: implications for clinical management. JAMA (2000) 284:223–228.
   PubMed Web of Science ®Google Scholar
• KELLEHER AD, CARR A, ZAUNDERS J, COOPER DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. j Infect. Dis. (1996) 173:321–329.
   PubMed Web of Science ®Google Scholar
• AUTRAN B, CARCELAIN G, LI et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science (1997) 277:112–116.
   PubMed Web of Science ®Google Scholar
• CONNORS M, KOVACS JA, KREVAT S etal.: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med. (1997) 3:533–540.
   Google Scholar
• LI TS, TUBIANA R, KATLAMA C, CALVEZ V, AIT MOHAND H, AUTRAN B: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet (1998) 351: 1682-1686.
   Google Scholar
• WILSON JD, IMAMI N, WATKINS A etal.: Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus Type 1 specificity equates with progression to disease. J. Infect. Dis. (2000) 182:792–798.
   Google Scholar
• •Initial indication that defects in the ability of CD4+ T-cells to proliferate and produce IL-2 rather than loss of HIV-1 specificity is associated with disease progression.
   Google Scholar
• APPAY V, NIXON DE DONAHOE SM et al.: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. (2000) 192:63–75.
   Google Scholar
• •Paper showing that defects in the cytolytic capacity of CD8+ T-cells but not the ability to produce antiviral cytokines is associated with disease progression. 11.GEA-BANACLOCHE JC, MIGUELES SA et al.: Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. Iminuriol. (2000) 165:1082–1092.
   Google Scholar
• •See reference [10] for annotation.
   Google Scholar
• KALAMS SA, WALKER BD: The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. (1998) 188:2199–2204.
   PubMed Web of Science ®Google Scholar
• ROSENBERG ES, BILLINGSLEY JM, CALIENDO et aL: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 278:1447–1450.
   PubMed Web of Science ®Google Scholar
• •Studies showing a statistically significant negative correlation between plasma viraemia and virus-specific CD4+ T-helper cells. Furthermore, early institution of potent anti-retroviral therapy is shown to lead to persistent, strong HIV-1-specific T-helper cell responses, analogous to those seen in long-term nonprogressors.
   Google Scholar
• OXENIUS A, PRICE DA, EASTERBROOK et al.: Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Nati Acad. Sri. USA (2000) 97:3382–3387.
   PubMed Web of Science ®Google Scholar
• MALHOTRA U, BERREY MM, HUANG Y et al.: Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus Type 1 infection. Infect. Dis. (2000) 181:121–131.
   Google Scholar
• LORI F, LEWIS MG, XU J et al.: Control of SIV rebound through structured treatment interruptions during early infection. Science (2000) 290:1591–1593.
   PubMed Web of Science ®Google Scholar
• ROSENBERG ES, ALTFELD M, POON SH et al.: Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 407:523–526.
   PubMed Web of Science ®Google Scholar
• •Studies showing that early institution of potent anti-retroviral drug therapy leads to preservation of strong HIV-1-specific T-cell responses, which were maintained even after anti-retroviral therapy is stopped. Furthermore, this was associated with control over viral replication.
   Google Scholar
• CARMICHAEL A, JIN X, SISSONS E BORYSIEWICZ L: Quantitative analysis of the human immunodeficiency virus Type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. I Exp. Med. (1993) 177: 249–255.
   PubMed Web of Science ®Google Scholar
• WILLS MR, CARMICHAEL AJ, MYNARD K et al.: The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. Viral. (1996) 70:7569–7579.
   PubMed Web of Science ®Google Scholar
• JINX, RAMANATHAN M JE, BARSOUM S et al.: Safety and immunogenicity study of vCP1452/rgp160 therapeutic vaccines in patients treated with HAART for over two years. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4–8, 2001, Chicago, Illinois. Abstract 21. (Available at: http:// www.retroconference.org/2001/abstracts/ abstracts/abstracts/21.htm)
   Google Scholar
• MARKOWITZ M, JIN X, RAMRATNAM B etal.: Prolonged HAART initiated within 120 days of primary HIV-1 infection does not result in sustained control of HIV-1 after cessation of therapy. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4–8, 2001, Chicago, Illinois. Abstract 288. (Available at: http:// www.retroconference.org/2001/abstracts/ abstracts/abstracts/288.htm)
   Google Scholar
• IMAMI N, HARDY G, BURTON C et al:Immune responses and reconstitution in HIV-1 infected individuals: impact of antiretroviral therapy, cytokines and therapeutic vaccination. Inunutial. Lett. (In Press).
   Google Scholar
• MCMICHAEL AJ, GOTCH FM, NOBLE GR, BEARE PA: Cytotoxic T-cell immunity to influenza. N Engl. I Med. (1983) 309:13–17.
   PubMed Web of Science ®Google Scholar
• MATLOUBIAN M, CONCEPCION RJ, AHMED R: CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. I Viral. (1994) 68:8056–8063.
   Google Scholar
• BATTEGAY M, MOSKOPHIDIS D, RAHEMTULLA A, HENGARTNER H, MAK TW, ZINKERNAGEL RM: Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. Viral. (1994) 68:4700–4704.
   PubMed Web of Science ®Google Scholar
• ZAJAC AJ, BLATTMAN JN, MURALI-KRISHNA K et al.: Viral immune evasion due to persistence of activated T cells without effector function. I Exp. Med. (1998) 188:2205–2213.
   PubMed Web of Science ®Google Scholar
• GOULDERPJR, ROWLAND-JONES SL, MCMICHAEL AJ, WALKER BD: Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS (1999) 13(Suppl. P):5121–5136.
   Google Scholar
• KALAMS SA, BUCHBINDER SP, ROSENBERG et al.: Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus Type 1 infection. Viral. (1999) 73:6715–6720.
   PubMed Web of Science ®Google Scholar
• RIDGE JP, DI ROSA F, MATZINGER P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393:474–478.
   PubMed Web of Science ®Google Scholar
• HAASE AT: Population biology of HIV-1infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Ann. Rev Inanunal. (1999) 17:625–656.
   PubMed Web of Science ®Google Scholar
• BERGER EA, MURPHY PM, FARBER JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Ann. Rev Inununol. (1999) 17:657–700.
   PubMed Web of Science ®Google Scholar
• LIVINGSTONE WJ, MOORE M, INNES D, BELL JE, SIMMONDS P: Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group. Lancet (1996) 348:649–654.
   PubMed Web of Science ®Google Scholar
• FLAMAND L, CROWLEY RW, LUSSO P, COLOMBINI-HATCH S, MARGOLIS DM, GALLO RC: Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. Proc. Nati Acad. Sri. USA (1998) 95:3111–3116.
   PubMed Web of Science ®Google Scholar
• BALASUBRAMANIAN S, JIANG Q, SANCHEZ-DARDON J, HAWLEY-FOSS N, COPELAND KFT: The effects of HIV-1 infection of CD8+T cells on cellular function. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4–8, 2001, Chicago, Illinois. Abstract 175. (Available at: http:// www.retroconference.org/2001/abstracts/ abstracts/abstracts/175.htm)
   Google Scholar
• LEVY JA: Pathogenesis of human immunodeficiency virus infection. Microbial. Rev (1993) 57:183–289.
   PubMedGoogle Scholar
• PIERSON T, MCARTHUR J, SILICIANO RF: Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Ann. Rev Inanunal. (2000) 18:665–708.
   PubMed Web of Science ®Google Scholar
• •Review describing life-long persistence of latent reservoirs of HIV-1, even in patients on effective anti-retroviral therapy.
   Google Scholar
• HAYNES BF, MARKERT ML, SEMPOWSKI GD, PATEL DD, HALE LP: The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu. Rev. Inanunal. (2000) 18:529–560.
   PubMed Web of Science ®Google Scholar
• KNIGHT SC, PATTERSON S: Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology. Annu. Rev Inanunal. (1997) 15:593–615.
   PubMed Web of Science ®Google Scholar
• BROWN JH, JARDETZKY TS, GORGA JC et al.: Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature (1993) 364:33–39.
   PubMed Web of Science ®Google Scholar
• MOSS PA, ROWLAND-JONES SL, FRODSHAM PM et al.: Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc. Natl. Acad. Sci. USA (1995) 92:5773–5777.
   PubMed Web of Science ®Google Scholar
• KLEIN MR, VAN BAALEN CA, HOLWERDA AM et al.: Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. Exp. Med. (1995) 181:1365–1372.
   PubMed Web of Science ®Google Scholar
• MCMICHAEL AJ, PHILLIPS RE: Escapeof human immunodeficiency virus from immune control. Annu. Rev. Immunol (1997) 15:271–296.
   PubMed Web of Science ®Google Scholar
• BRODIE SJ, LEWINSOHN DA, PATTERSON BK et al: In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med. (1999) 5:34–41.
   PubMed Web of Science ®Google Scholar
• TOWNSEND AR, GOTCH FM, DAVEY J: Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell (1985) 42:457–467.
   PubMed Web of Science ®Google Scholar
• BERKE G: The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu. Rev Immunol (1994) 12:735–773.
   PubMed Web of Science ®Google Scholar
• SHRESTA S, PHAM CT, THOMAS DA, GRAUBERT TA, LEY TJ: How do cytotoxic lymphocytes kill their targets? Cun: Opin. Immunol (1998) 10:581–587.
   Web of Science ®Google Scholar
• WALKER CM, MOODY DJ, STITES DE LEVY JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 234:1563–1566.
   PubMed Web of Science ®Google Scholar
• LEVY JA, MACKEWICZ CE, BARKER E: Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immutiol Today (1996) 17:217–224.
   PubMedGoogle Scholar
• WILKINSON J, ZAUNDERS JJ, CARR A, COOPER DA: CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia. j Infect. Dis. (1999) 180:68–75.
   PubMed Web of Science ®Google Scholar
• BARKER E, BOSSART KN, FUJIMURA SH, LEVY JA: CD28 costimulation increases CD8+ cell suppression of HIV replication. j Immutiol (1997) 159:5123–5131.
   PubMed Web of Science ®Google Scholar
• BERGER EA, DOMS RW, FENYO EM et al.: A new classification for HIV-1. Nature (1998) 391:240.
   PubMed Web of Science ®Google Scholar
• BALLET JJ, COUDERC LJ, RABIAN-HERZOG et al.: Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy. AIDS (1988) 2:291–297.
   PubMed Web of Science ®Google Scholar
• GIORGI JV, FAHEY JL, SMITH et al: Early effects of HIV on CD4 lymphocytes in vivo. J. Immunol (1987) 138:3725–3730.
   PubMed Web of Science ®Google Scholar
• BE VAN MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. j Exp. Med. (1976) 143:1283–1288.
   PubMed Web of Science ®Google Scholar
• BENNETT SR, CARBONE FR, KARAMALIS F, MILLER JF, HEATH WR: Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. j Exp. Med. (1997) 186:65–70.
   PubMed Web of Science ®Google Scholar
• CHOUGNET C, COHEN SS, KAWAMURA T et al: Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. Immunol (1999) 163:1666–1673.
   Web of Science ®Google Scholar
• LYLES RH, MUNOZ A, YAMASHITA et al.: Natural history of human immunodeficiency virus Type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. j Infect. Dis. (2000) 181:872–80.
   PubMed Web of Science ®Google Scholar
• KOUP RA, SAFRIT JT, CAO Y et al: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus Type 1 syndrome. J. Viral. (1994) 68:4650–4655.
   PubMed Web of Science ®Google Scholar
• BORROW E LEWICKI H, WEI X et al: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med (1997) 3:205–211.
   PubMed Web of Science ®Google Scholar
• JIN X, BAUER DE, ILITTLETON SE et al.: Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. Exp. Med (1999) 189:991–998.
   PubMed Web of Science ®Google Scholar
• SCHMITZ JE, KURODA MJ, SANTRA S etal.: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 283:857–860.
   Google Scholar
• ALLEN TM, O& CONNOR DH, JINGP et al.: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 407:386–390.
   Google Scholar
• KELLEHER AD, LONG C, HOLMES EC et al.: Clustered mutations in HIV-1 gag are consistently required for escape from HLA- B27-restricted cytotoxic T lymphocyte responses. j Exp. Med. (2001) 193:375–386.
   PubMed Web of Science ®Google Scholar
• BUCHBINDER SP, KATZ MH, HESSOL NA, O'MALLEY PM, HOLMBERG SD. Long-term HIV-1 infection without immunologic progression. AIDS (1994) 8:1123–1128.
   Google Scholar
• LEFRERE JJ, MORAND-JOUBERT L, MARIOTTI M etal.: Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood (1997) 90:1133–1140.
   Google Scholar
• LIU R, PAXTON WA, CHOE S et al: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 86:367–377.
   PubMed Web of Science ®Google Scholar
• DEACON NJ, TSYKIN A, SOLOMON A et al.: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 270:988–991.
   PubMed Web of Science ®Google Scholar
• ALEXANDER L, WEISKOPF E, GREENOUGH TC et al: Unusual polymorphisms in human immunodeficiency virus Type 1 associated with nonprogressive infection. I Viral. (2000) 74:4361–4376.
   Google Scholar
• GREENOUGH TC, SULLIVAN JL, DESROSIERS RC: Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl. J. Med. (1999) 340:236–237.
   PubMed Web of Science ®Google Scholar
• RINALDO C, HUANG X-L, FAN ZF et al.: High levels of anti-human immunodeficiency virus Type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. j Viral. (1995) 69:5838–5842.
   PubMed Web of Science ®Google Scholar
• HARRER T, HARRER E, KALAMS SA et al.: Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. j brununol. (1996) 156:2616–2623.
   Google Scholar
• BARKER E, MACKEWICZ CE, REYES-TERAN G et al: Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood (1998) 92:3105–3114.
   PubMed Web of Science ®Google Scholar
• MIGUELES SA, SABBAGHIAN MS, SHUPERT WL et al.: HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Nati Acad. Sci. USA (2000) 97:2709–2714.
   PubMed Web of Science ®Google Scholar
• CLERICI M, STOCKS NI, ZAJAC RA et al.: Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature (1989) 339:383–385.
   PubMed Web of Science ®Google Scholar
• CLERICI M, STOCKS NI, ZAJAC RA et al.: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. OM. Invest. (1989) 84:1892–1899.
   Google Scholar
• MUSEY L, HUGHES J, SCHACKER T, SHEA T, COREY L, MCELRATH MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus Type 1 infection. N. Engl. J Med. (1997) 337:1267–1274.
   PubMed Web of Science ®Google Scholar
• CHAMPAGNE P, OGG GS, KING AS et al.: Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (2001) 410:106–111.
   PubMed Web of Science ®Google Scholar
• •Studies suggesting a selective defect in HIV-1 infection in the maturation of fully responsive CD8+ effector cells.78. VAN BAARLE D, KOSTENSE S, HOVENKAMP E, KNOL GJ, VAN OERS MHJ, MIEDEMA F: Lack of differentiation of virus-specific CD8+ T cells into CD27-effector cells is associated with progression to disease. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4–8, 2001, Chicago, Illinois. Abstract 275. (Available at: http:// www.retroconference.org/2001/abstracts/ abstracts/abstracts/275.htm)
   Google Scholar
• FINZI D, HERMANKOVA M, PIERSON T etal.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 278:1295–1300.
   Google Scholar
• FINZI D, BLANKS ON J, SILICIANO JDet al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med. (1999) 5:512–517.
   Google Scholar
• •Paper describes measurements of the decay rate of the latent reservoir of HIV-1 in treated individuals. Half-life of the latent reservoir was calculated to be 43.9 months.81.RAMRATNAM B, MITTLER JE, ZHANG L et al.: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Med. (2000) 6:82–85.
   Google Scholar
• KOVACS JA, BASELER M, DEWAR RJ et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl. I Med. (1995) 332:567–575.
   PubMed Web of Science ®Google Scholar
• HUZICKA I: Could bone marrow transplantation cure AIDS? Med. Hypotheses (1999) 52:247–257.
   PubMed Web of Science ®Google Scholar
• IRAUGER RJ, FERRE F, DAIGLE AE et al.: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus Type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect. Dis. (1994) 169:1256–1264.
   PubMed Web of Science ®Google Scholar
• TRAUGER RJ, DAIGLE AE, GIERMAKOWSKA W etal.: Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial. ..J. Acquit: Immune. Defic. Syndr. Hum. Retrovirol. (1995) 10 (Suppl. 2):574–82.
   Google Scholar
• SAAG MS: The role of immunotherapy in the treatment of HIV. AIDS (2001) 15 (Suppl. 2):S1–53.
   Google Scholar
• REDFIELD RR, BIRX DL, KETTER N et al.: A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl. J Med. (1991) 324:1677–1684.
   PubMed Web of Science ®Google Scholar
• FAGARD C, LEBRAZ M, GUNTHARD H et al.: SSITT: a prospective trial of strategic treatment interruptions in 128 patients. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4–8, 2001, Chicago, Illinois. Abstract 357. (Available at: http:// www.retroconference.org/2001/abstracts/ abstracts/abstracts/357.htm)
   Google Scholar
• IMAMI N, HARDY GAD, NELSON MR et al.: Induction of HIV-1-specific T-cell responses by administration of cytokines in late-stage patients receiving highly active antiretroviral therapy. Clin Exp. Immunol (1999) 118:78–86.
   PubMed Web of Science ®Google Scholar
• DENIS-MIZE KS, DUPUIS M, MACKICHAN ML et al.: Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. (2000) 7:2105–2112.
   PubMed Web of Science ®Google Scholar
• TURNER JL, TRAUGER RJ, DAIGLE AE, CARLO DJ: HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS (199 4) 8:1429-1435.
   Google Scholar
• LEVINE AM, GROSHEN S, ALLEN J et al.: Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up. I Acquir: Immune Defic. Syndr. Hum. Retrovirol. (1996) 11:351–364.
   Google Scholar
• MOSS RB, TRAUGER RJ, GIERMAKOWSKA WK et al.: Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection. I Acquit: Immune Defic. Syndr. Hum. Retrovirol. (1997) 14:343–350.
   Google Scholar
• CHURDBOONCHART V, SAKONDHAVAT C, KULPRADIST S et al.: A double-blind, adjuvant-controlled trial of human immunodeficiency virus Type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of 300. Clin. Diagn Lab. Immunol. (2000) 7:728–733.
   PubMedGoogle Scholar
• MOSS RB, WALLACE MR, GIERMAKOWSKA WK etal.: Phenotypic analysis of human immunodeficiency virus (HIV) Type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.j Infect. Dis. (1999) 180:641–648.
   Google Scholar
• KAHN JO, CHERNG DW, MAYER K, MURRAY H, LAGAKOS S: Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA (2000) 284:2193–2202.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-CRUZ E, MUNOZ-FERNANDEZ MA, NAVARRO J et al.: Randomized control Phase II trial evaluating HIV-1 immunogen administered to patients with HIV-1 chronic infection having 300 to 700 cells/p1CD4 cell counts: Data from a recently unblinded study. Expert Op/n. Biol. Ther. (2001) 1(5) Program and abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment, July 8–11, 2001, Buenos Aires, Argentina.
   Google Scholar
• TURNER JL, KOSTMAN JR, AQUINO A et al.: The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomised, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med. (2001) 2:68–77.
   PubMedGoogle Scholar
• •Paper showing that recipients of the HIV-1 immunogen had a significantly greater decline in viral load, and significantly enhanced HIV-1-specific CD4+ T cell responses.
   Google Scholar
• MOSS RB, DIVELEY J, JENSEN FC, GOUVEIA E, CARLO DJ. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA. j Hum. Viral. (2001) 4:39-43. ma SMITH DE, BOAG F, COLEBUNDERS R. Therapeutic vaccination (p24 VLP) of patients with advanced HIV-1 infection does not alter CD4 decline. AIDS (1996) 10 (Suppl. 2):514. Dm. VEENSTRA J, WILLIAMS IG, COLEBUNDERS R et al.: Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. j Infect. Dis. (1996) 174:862–866.
   Google Scholar
• PETERS BS, CHEINGSONG-POPOV R, CALLOW D et al: A pilot Phase II study of the safety and immunogenicity of HIV p17/ p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. j Infect (1997) 35:231–235.
   PubMed Web of Science ®Google Scholar
• KLEIN MR, VEENSTRA J, HOLWERDA AM et al: Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV Type 1-seropositive individuals. AIDS Res. Hum. Retraviruses (1997) 13:393–399.
   PubMed Web of Science ®Google Scholar
• KELLEHER AD, ROGGENSACK M, JARAMILLO AB et al.: Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators. AIDS (1998) 12:175–182.
   Google Scholar
• BISELLI R, LOOMIS LD, DEL BONO V, BURKE DS, REDFIELD RR, BIRX DL: Immunization of HIV-infected patients with rgp160: modulation of anti-rgp120 antibody spectrotype. j Acquir. Immune Defic. Synth: (1994) 7:1016–1024.
   Google Scholar
• KUNDU SK, KATZENSTEIN D, VALENTINE FT, SPINO C, EFRON B, MERIGAN TC: Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. j Acquir. Immune Defic. Syridr. Hum. Retraviral (1997) 15:269–274.
   PubMed Web of Science ®Google Scholar
• WAHREN B, BRATT G, PERSSON C et al.: Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. j AIDS (1994) 7:220-229. ma. SITZ KV, RATTO-KIM S, HODGKINS AS, ROBB ML, BIRX DL: Proliferative responses to human immunodeficiency virus Type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. J. Infect. Dis. (1999) 179:817–824.
   Google Scholar
• BIRX DL, LOOMIS-PRICE LD, ARONSON N et al: Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. Infect. Dis. (2000) 181:881–889.
   PubMed Web of Science ®Google Scholar
• ORENTAS RJ, HILDRETH JE, OBAH E etal.: Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science (1990) 248:1234–1237.
   Google Scholar
• DOLIN R, GRAHAM BS, GREENBERG SB etal.: The safety and immunogenicity of a human immunodeficiency virus Type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann. Intern. Med. (1991) 114:119–127.
   Google Scholar
• TSOUKAS CM, RABOUD J, BERNARD NF et al.: Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. AIDS Res. Hum. Retraviruses (1998) 14:483–490.
   PubMed Web of Science ®Google Scholar
• PONTESILLI 0, GUERRA EC, AMMASSARI A et al: Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team. AIDS (1998) 12:473–480.
   Google Scholar
• LEANDERSSON AC, BRATT G, HINKULA J etal.: Induction of specific T-cell responses in HIV infection. AIDS (1998) 12:157–166.
   Google Scholar
• SANDSTROM E, WAHREN B: Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 353:1735–1742.
   PubMed Web of Science ®Google Scholar
• MACGREGOR RR, BOYER JD, UGEN KE etal.: First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus Type 1 infection: safety and host response. j Infect. Dis. (1998) 178:92–100.
   Google Scholar
• CALAROTA S, BRATT G, NORDLUND S et al.: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 351:1320–1325.
   PubMed Web of Science ®Google Scholar
• CALAROTA SA, LEANDERSSON AC, BRATT G et al: Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. Immune]. (1999) 163:2330–2338.
   PubMed Web of Science ®Google Scholar
• HANKE T, MCMICHAEL A: Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immune]. Lett. (1999) 66:177–81.
   PubMed Web of Science ®Google Scholar
• WU S, PASCUAL DW, LEWIS GK, HONE DM: Induction of mucosal and systemic responses against human immunodeficiency virus Type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector. AIDS Res. Hum. Retraviruses (1997) 13:1187–1194.
   PubMed Web of Science ®Google Scholar
• RUIZ L, MARTINEZ-PICADO J, ROMEU J et al.: Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS (2000) 14:397–403.
   PubMed Web of Science ®Google Scholar
• ANGEL JB: Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies. The AIDS Reader (2001) 11:209–221.
   PubMedGoogle Scholar